US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
ATE135397T1
(de)
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
JP2919890B2
(ja)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
SE509359C2
(sv)
|
1989-08-01 |
1999-01-18 |
Cemu Bioteknik Ab |
Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5891693A
(en)
|
1990-01-25 |
1999-04-06 |
Alusuisse Holdings A.G. |
Recombinant DNA methods vectors and host cells
|
DE69132925T2
(de)
|
1990-08-29 |
2002-10-10 |
Ct Hospitalier Regional De Nan |
An stabile proteinkernstruktur gebundene proteinpolyliganden
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5639635A
(en)
|
1994-11-03 |
1997-06-17 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
WO1997038123A1
(en)
|
1996-04-05 |
1997-10-16 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
DE19701141C1
(de)
|
1997-01-16 |
1998-04-09 |
Hoechst Ag |
Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
JP2002510481A
(ja)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
抗体変異体及びその断片
|
EP2261229A3
(en)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
IT1306736B1
(it)
|
1999-10-29 |
2001-10-02 |
Benito Salmi |
Dispositivo di contenimento e distribuzione di palloni per tiri alvolo.
|
US6399219B1
(en)
|
1999-12-23 |
2002-06-04 |
Vapor Technologies, Inc. |
Article having a decorative and protective coating thereon
|
AU767394C
(en)
|
1999-12-29 |
2005-04-21 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20040014652A1
(en)
|
2000-06-01 |
2004-01-22 |
Andre Trouet |
Tumor activated prodrug compounds and methods of making and using the same
|
DE10045592A1
(de)
|
2000-09-15 |
2002-03-28 |
Klaus Pfizenmaier |
Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CN101940189A
(zh)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン,エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
GB0100551D0
(en)
|
2001-01-09 |
2001-02-21 |
Queen Mary & Westfield College |
Protein
|
WO2002076489A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
WO2003030821A2
(en)
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ES2326964T3
(es)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
Composiciones de glicoproteina.
|
KR101271635B1
(ko)
*
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
JP5424521B2
(ja)
|
2001-12-21 |
2014-02-26 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
WO2003085119A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
EP1539941A4
(en)
*
|
2002-08-27 |
2006-11-29 |
|
ADZYMES AND THEIR USES
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
JP2006518583A
(ja)
|
2002-10-14 |
2006-08-17 |
エフ.ホフマン−ラ ロシュ アーゲー |
Il−15アンタゴニスト
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
JP2006520584A
(ja)
|
2002-11-08 |
2006-09-14 |
アブリンクス エン.ヴェー. |
安定化単一ドメイン抗体
|
PL212899B1
(pl)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
|
MXPA05006945A
(es)
|
2002-12-26 |
2005-12-14 |
Mountain View Pharmaceuticals |
Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
|
UA90654C2
(ru)
*
|
2002-12-26 |
2010-05-25 |
Маунтин Вью Фармасьютикалз, Инк. |
Полимерные конъюгаты интерферона-бета с повышенной биологической активностью
|
WO2004090135A2
(en)
|
2003-04-09 |
2004-10-21 |
Asterion Limited |
Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
JPWO2005053742A1
(ja)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
抗体組成物を含有する医薬
|
AU2005211725B2
(en)
|
2004-02-09 |
2010-07-15 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP3623473A1
(en)
|
2005-03-31 |
2020-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
WO2006110728A2
(en)
|
2005-04-12 |
2006-10-19 |
The Uab Research Foundation |
Immunogenic cmv tegument aggregates
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
CA2654055A1
(en)
|
2006-06-07 |
2007-12-21 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1867660A1
(en)
*
|
2006-06-14 |
2007-12-19 |
CSL Behring GmbH |
Proteolytically cleavable fusion protein comprising a blood coagulation factor
|
CN101557817A
(zh)
*
|
2006-09-14 |
2009-10-14 |
人类基因科学公司 |
清蛋白融合蛋白
|
AU2007294805A1
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080302732A1
(en)
|
2007-05-24 |
2008-12-11 |
Hyongsok Soh |
Integrated fluidics devices with magnetic sorting
|
JP2010536341A
(ja)
*
|
2007-08-15 |
2010-12-02 |
アムニクス, インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
CA3128656A1
(en)
*
|
2007-08-22 |
2009-02-26 |
The Regents Of The University Of California |
Activatable binding polypeptides and methods of identification and use thereof
|
US20110172165A1
(en)
|
2008-02-19 |
2011-07-14 |
Peter Artymiuk |
Modified linkers
|
WO2010014258A2
(en)
|
2008-08-01 |
2010-02-04 |
Nektar Therapeutics Al, Corporation |
Conjugates having a releasable linkage
|
GB0815216D0
(en)
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
CN102482347B
(zh)
|
2009-01-12 |
2017-04-26 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
EP2398494A4
(en)
|
2009-02-23 |
2015-10-28 |
Cytomx Therapeutics Inc |
Proproteins and their methods of use
|
EP2456787A4
(en)
|
2009-07-24 |
2013-01-30 |
Univ Leland Stanford Junior |
CYTOKINE COMPOSITIONS AND METHODS OF USE
|
BR112012008444A2
(pt)
|
2009-10-10 |
2019-09-24 |
Eleven Biotherapeutics Inc |
proteína isolada, composição farmacêutica, métodos para modular uma resposta imune ou inflamatória em um sujeito, para tratar um distúrbio mediado po ir-17 em um sujeito e para preparar uma proteína recombinante, ácido nucleico isolado, e, célula hospedeira recombinante
|
EP2553101A4
(en)
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
CYTOKINES ACTIVATED BY PROTEASES
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
AU2011316786A1
(en)
|
2010-10-22 |
2013-05-02 |
Protox Therapeutics Corp. |
Use of human serum albumin to decrease antigenicity of therapeutic proteins
|
US20130225496A1
(en)
|
2010-11-01 |
2013-08-29 |
Novozymes Biopharma Dk A/S |
Albumin Variants
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
WO2012088302A2
(en)
*
|
2010-12-22 |
2012-06-28 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
RU2713121C2
(ru)
|
2012-04-27 |
2020-02-03 |
Сайтомкс Терапьютикс, Инк. |
Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
|
JP5329728B1
(ja)
|
2012-05-18 |
2013-10-30 |
太平工業株式会社 |
丸刃および/またはスペーサーを分離するための分離機構、ハンドリングロボット、保管台および分離方法
|
RU2015101803A
(ru)
|
2012-06-22 |
2016-08-20 |
Сайтомкс Терапьютикс, Инк. |
Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
JP6445434B2
(ja)
|
2012-08-09 |
2018-12-26 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
スーパーカインおよびシンセカイン:新規かつ増強されたシグナル伝達活性を有する再利用されるサイトカイン
|
WO2014026136A2
(en)
|
2012-08-10 |
2014-02-13 |
Cytomx Therapeutics, Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
WO2014094799A1
(en)
*
|
2012-12-19 |
2014-06-26 |
Scil-Proteins-Gmbh |
Ubiquitin moieties as a means for prolonging serum half-life
|
CA2896282C
(en)
|
2013-01-04 |
2021-07-20 |
Cytomx Therapeutics, Inc. |
Compositions and methods for detecting protease activity in biological systems
|
WO2014120555A1
(en)
|
2013-01-31 |
2014-08-07 |
The Regents Of The University Of California |
Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
JP6660294B2
(ja)
|
2013-06-04 |
2020-03-11 |
シトムクス セラピューティクス,インコーポレイティド |
活性化可能抗体を結合するための組成物及び方法
|
PT3406633T
(pt)
|
2013-07-25 |
2022-05-04 |
Cytomx Therapeutics Inc |
Anticorpos multi-específicos, anticorpos ativáveis multi-específicos e métodos de utilização dos mesmos
|
MX2016003957A
(es)
|
2013-09-25 |
2017-02-02 |
Cytomx Therapeutics Inc |
Substratos de metaloproteinasas de matriz y otras porciones escindibles y metodos para usar los mismos.
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
IL270562B
(en)
|
2014-01-31 |
2022-08-01 |
Cytomx Therapeutics Inc |
Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses
|
HUE053982T2
(hu)
|
2014-02-21 |
2021-08-30 |
Nektar Therapeutics India Pvt Ltd |
IL-2Rß-szelektív agonisták egy anti-CTLA-4 antitesttel vagy egy anti-PD-1 antitesttel kombinációban
|
AU2015231170B2
(en)
*
|
2014-03-20 |
2019-10-03 |
Bristol-Myers Squibb Company |
Serum albumin-binding fibronectin type III domains
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
EP3172235A2
(en)
|
2014-07-25 |
2017-05-31 |
Cytomx Therapeutics Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
MA41374A
(fr)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
|
KR20170135860A
(ko)
|
2015-03-13 |
2017-12-08 |
싸이톰스 테라퓨틱스, 인크. |
항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
|
AU2016246152A1
(en)
*
|
2015-04-10 |
2017-11-02 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
CA2975333A1
(en)
*
|
2015-04-22 |
2016-10-27 |
Curevac Ag |
Rna containing composition for treatment of tumor diseases
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
PL3292150T3
(pl)
|
2015-05-04 |
2020-07-13 |
Cytomx Therapeutics Inc. |
Przeciwciała anty-cd166, aktywowalne przeciwciała anty-cd166 i ich sposoby stosowania
|
CN108026170B
(zh)
|
2015-05-04 |
2022-03-01 |
西托姆克斯治疗公司 |
抗cd71抗体、可活化抗cd71抗体及其使用方法
|
JP6688551B2
(ja)
|
2015-05-21 |
2020-04-28 |
ハープーン セラピューティクス,インク. |
三重特異性結合タンパク質と使用方法
|
US20160362469A1
(en)
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
JP7014706B2
(ja)
|
2015-07-13 |
2022-02-01 |
サイトメックス セラピューティクス インコーポレイテッド |
抗pd-1抗体、活性化可能抗pd-1抗体、およびその使用方法
|
KR102501921B1
(ko)
|
2016-03-08 |
2023-02-21 |
매버릭 테라퓨틱스, 인크. |
유도성 결합 단백질 및 사용 방법
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
AU2017301880C1
(en)
*
|
2016-07-29 |
2022-04-21 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
CN107759697B
(zh)
*
|
2016-08-19 |
2023-03-24 |
安源医药科技(上海)有限公司 |
制备融合蛋白的方法
|
WO2018071919A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
IL15/IL15Rα HETERODIMERIC FC-FUSION PROTEINS
|
US20190225702A1
(en)
|
2016-10-14 |
2019-07-25 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
EP3535300A1
(en)
|
2016-11-03 |
2019-09-11 |
Bristol-Myers Squibb Company |
Activatable anti-ctla-4 antibodies and uses thereof
|
CA3039316A1
(en)
*
|
2016-11-28 |
2018-05-31 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand binding activity
|
WO2018136725A1
(en)
|
2017-01-19 |
2018-07-26 |
Harpoon Therapeutics, Inc. |
Innate immune cell inducible binding proteins and methods of use
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
KR20190121773A
(ko)
|
2017-03-01 |
2019-10-28 |
넥타르 테라퓨틱스 |
입양 세포 이식 요법과 조합된 인터루킨-2 수용체 알파, 베타 선택성 효현제를 이용한 면역 요법적 종양 치료 방법
|
JP2020511130A
(ja)
|
2017-03-09 |
2020-04-16 |
サイトメックス セラピューティクス インコーポレイテッド |
Cd147抗体、活性化可能cd147抗体、ならびにその作製および使用の方法
|
CA3062291A1
(en)
|
2017-05-02 |
2018-11-08 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
JP7316222B2
(ja)
|
2017-05-15 |
2023-07-27 |
ネクター セラピューティクス |
長時間作用型インターロイキン-15受容体作動薬並びに関連する免疫治療組成物及び方法
|
JP2020522486A
(ja)
|
2017-06-01 |
2020-07-30 |
サイトメックス セラピューティクス インコーポレイテッド |
活性化可能抗pdl1抗体、およびその使用方法
|
CN111050803A
(zh)
|
2017-06-20 |
2020-04-21 |
德克萨斯大学***董事会 |
用于治疗癌症的干扰素前药
|
CN111133006A
(zh)
|
2017-07-14 |
2020-05-08 |
西托姆克斯治疗公司 |
抗cd166抗体及其用途
|
CN110998329A
(zh)
|
2017-07-20 |
2020-04-10 |
西托姆克斯治疗公司 |
定性和/或定量分析可活化抗体的特性的方法及其用途
|
AU2018316694A1
(en)
|
2017-08-17 |
2020-02-13 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
CA3074112A1
(en)
|
2017-08-30 |
2019-03-07 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
US20210154277A1
(en)
|
2017-11-07 |
2021-05-27 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
CU24554B1
(es)
|
2018-05-07 |
2021-11-04 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
|
CN112654635A
(zh)
|
2018-05-14 |
2021-04-13 |
狼人治疗公司 |
可活化细胞因子多肽及其使用方法
|
CA3100007A1
(en)
*
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
KR20210038548A
(ko)
|
2018-06-22 |
2021-04-07 |
큐진 인크. |
사이토카인-기반 생체활성 약물 및 이의 사용 방법
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
EP3983432A1
(en)
|
2019-06-12 |
2022-04-20 |
Askgene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
US20220267400A1
(en)
|
2019-07-25 |
2022-08-25 |
Trutino Biosciences Inc |
Il-2 cytokine prodrugs comprising a cleavable linker
|
WO2021030483A1
(en)
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Il-2 fusion proteins that preferentially bind il-2ralpha
|
WO2021202675A1
(en)
|
2020-04-01 |
2021-10-07 |
Xilio Development, Inc. |
Masked il-2 cytokines and their cleavage products
|
JP2023520514A
(ja)
|
2020-04-01 |
2023-05-17 |
エクシリオ デベロップメント, インコーポレイテッド |
マスク型il-15サイトカインおよびその切断産物
|
CN115734806A
(zh)
|
2020-04-01 |
2023-03-03 |
西里欧发展公司 |
掩蔽的il-12细胞因子和其切割产物
|